DIAGNOS Gets the Green Light for the Use of its Diabetic Retinopathy Screening Technology in Quebec Hospitals

BROSSARD, Quebec, January 31, 2023 (GLOBE NEWSWIRE) — Diagnos Inc. (”

DIAGNOSIS

“, the ”

group

“or “we”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in the early detection of critical health issues through the use of its FL

AI

RE platform based on artificial intelligence (

AI

), is pleased to announce that the Government of Quebec has given the go-ahead for Diagnos artificial intelligence (AI) technology to screen and assess diabetic retinopathy patients identified by the endocrinology departments of hospitals across the province be taken care of.

This positive milestone is the result of a collaborative project initiated in 2018 using Diagnos’ technology to assess and classify the severity of diabetic retinopathy in patients in the endocrinology department of a major Quebec hospital.

The pilot phase of the project was successfully completed, leading to the preparation of a final report by government officials. This report has been distributed to all hospitals in the province and highlights the cost savings and other benefits of implementing DIAGNOS technology. Specifically, the report found that the use of DIAGNOS’ technology resulted in cost savings of $85 per patient, as well as additional savings from optimizing and reducing the time spent by medical staff.

“The project has been a long but rewarding journey for DIAGNOS, especially given the COVID-19 restrictions in the hospital’s endocrinology and ophthalmology departments. We are delighted that the government is recognizing the value of our AI-based diabetic retinopathy screening solution. DIAGNOS will now start marketing it to all hospitals and clinics in the province,” he says

Mr.

André Larente, President of DIAGNOS

.

Larente continued, “We have been working tirelessly on this project since 2018 and are excited to bring Diagnos’ innovative solutions to the people of Quebec, especially given the province’s high rate of diabetes. Our solutions will make early detection and prevention of vision loss more accessible to the population, which is critical to the health and well-being of people with diabetes.”

According to Statistics Canada, Quebec has one of the highest rates of diabetes in the country, with over 1 million people living with diabetes. With such a large population of diabetics receiving endocrinology services in Quebec hospitals, the market potential for DIAGNOS’ AI screening solutions is significant.

About DIAGNOSTICS


DIAGNOS is a publicly traded Canadian company dedicated to the early detection of critical health issues based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for rapid modification and development of applications such as CARA (Computer Assisted Retina Analysis). CARA’s image enhancement algorithms deliver sharper, clearer and easier to analyze retinal images. CARA is a cost-effective tool for real-time screening of large patient populations. CARA has been cleared for marketing by the following regulatory agencies: Health Canada, FDA (US), CE (Europe), COFEPRIS (Mexico), and Saudi FDA (Saudi Arabia).

For more information, see

www.diagnos.com

and

www.sedar.com

For more information please contact:

Mr André Larente, President

DIAGNOS Inc.

Tel: 450 678-8882, ext. 224

Email: [email protected]

This press release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this press release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/87001ed4-5039-44c7-a5aa-dc862016216b